Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Freek D. Daams

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6323-6342; OpenAlex author ID A5084325687. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
116
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 6 papers · 2025: 4 papers · 2026: 7 papers

Papers 22

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Refining the Classroom: The Self-Supervised Professor Model for Improved Segmentation of Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s10278-025-01555-x↗
  3. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  4. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  5. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Last author DOI 10.1093/bjsopen/zrag057↗
  6. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  7. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  8. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  9. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  10. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  11. Computer-Aided Decision Support and 3D Models in Pancreatic Cancer Surgery: A Pilot Study. Co-author DOI 10.3390/jcm14051567↗
  12. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  13. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  14. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  15. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  16. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  17. Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy: A Single-Center Experience. Co-author DOI 10.1245/s10434-024-15591-4↗
  18. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel A… Co-author DOI 10.3390/cancers14020344↗
  19. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. Co-author DOI 10.1016/j.ejso.2020.11.137↗
  20. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled… Co-author DOI 10.1186/s13063-021-05248-y↗
  21. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. Co-author DOI 10.1634/theoncologist.2019-0680↗
  22. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. Co-author DOI 10.1148/radiol.2016152835↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 13 shared papers, 2017–2026 · strength 2.01
  2. Geert Kazemier M · 10 shared papers, 2017–2026 · strength 1.49
  3. Bas Groot Koerkamp · 8 shared papers, 2024–2026 · strength 1.37
  4. Thomas F. Stoop · 8 shared papers, 2024–2026 · strength 1.35
  5. Izaak Quintus Molenaar · 8 shared papers, 2021–2026 · strength 1.17
  6. Hjalmar C. van Santvoort · 8 shared papers, 2021–2026 · strength 1.17
  7. Ingmar Florin Rompen · 6 shared papers, 2024–2026 · strength 1.04
  8. Christopher Lee Wolfgang · 6 shared papers, 2024–2026 · strength 1.04
  9. Ammar A. Javed · 6 shared papers, 2024–2026 · strength 1.04
  10. Ignace H. J. T. de Hingh · 7 shared papers, 2021–2026 · strength 0.98
  11. Sebastiaan Festen · 7 shared papers, 2021–2026 · strength 0.96
  12. Casper H.J. van Eijck · 5 shared papers, 2024–2026 · strength 0.82
  13. Gijs A. Patijn · 6 shared papers, 2021–2026 · strength 0.79
  14. Martijn W.J. Stommel · 6 shared papers, 2021–2026 · strength 0.79
  15. Roeland F. de Wilde · 4 shared papers, 2024–2026 · strength 0.71
  16. Joseph R. Habib · 4 shared papers, 2024–2026 · strength 0.68
  17. Nabiha Akhlaq Mughal · 4 shared papers, 2024–2026 · strength 0.67
  18. J. Sven D. Mieog · 4 shared papers, 2024–2026 · strength 0.66
  19. Johanna W. Wilmink · 5 shared papers, 2021–2026 · strength 0.66
  20. Poya Ghorbani · 4 shared papers, 2021–2026 · strength 0.64
  21. Thijs J. Schouten · 4 shared papers, 2021–2026 · strength 0.56
  22. Oskar Franklin · 3 shared papers, 2026 · strength 0.56
  23. Ernesto Sparrelid · 3 shared papers, 2026 · strength 0.56
  24. Marco Del Chiaro · 3 shared papers, 2026 · strength 0.56
  25. Richard David Schulick · 3 shared papers, 2026 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.